An in-tumor genetic screen reveals that the BET bromodomain protein, BRD4, is a potential therapeutic target in ovarian carcinoma

Disrupting the Interaction of BRD4 with Diacetylated Twist Suppresses Tumorigenesis in Basal-like Breast Cancer

(2014) Jian Shi et al.   CANCER CELL

mTOR inhibitors and their clinical application in cervical, endometrial and ovarian cancers: A critical review

(2014) Nader Husseinzadeh et al.   GYNECOLOGIC ONCOLOGY

Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer

(2014) Irfan A. Asangani et al.   NATURE

Development of Serous Ovarian Cancer is Associated with the Expression of Homologous Recombination Pathway Proteins

(2014) Qingqing Ye et al.   PATHOLOGY & ONCOLOGY RESEARCH

Microenvironment and tumor cell plasticity: An easy way out

(2013) Maria Letizia Taddei et al.   CANCER LETTERS

Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers

(2013) Jakob Lovén et al.   CELL

Resistance to CDK2 Inhibitors Is Associated with Selection of Polyploid Cells in CCNE1-Amplified Ovarian Cancer

(2013) D. Etemadmoghadam et al.   CLINICAL CANCER RESEARCH

BET Bromodomain Inhibition of MYC-Amplified Medulloblastoma

(2013) P. Bandopadhayay et al.   CLINICAL CANCER RESEARCH

Knockdown of creatine kinase B inhibits ovarian cancer progression by decreasing glycolysis

(2013) Xu-Hui Li et al.   INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY

Phospho Switch Triggers Brd4 Chromatin Binding and Activator Recruitment for Gene-Specific Targeting

(2013) Shwu-Yuan Wu et al.   MOLECULAR CELL

Emerging landscape of oncogenic signatures across human cancers

(2013) Giovanni Ciriello et al.   NATURE GENETICS

BET Inhibition Silences Expression of MYCN and BCL2 and Induces Cytotoxicity in Neuroblastoma Tumor Models

(2013) Anastasia Wyce et al.   PLoS One

Targeting MYCN in Neuroblastoma by BET Bromodomain Inhibition

(2013) Alexandre Puissant et al.   Cancer Discovery

Over-expressions of AMPK subunits in ovarian carcinomas with significant clinical implications

(2012) Cuilan Li et al.   BMC CANCER

Minireview: Human Ovarian Cancer: Biology, Current Management, and Paths to Personalizing Therapy

(2012) Ignacio Romero et al.   ENDOCRINOLOGY

Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins

(2012) W. W. Lockwood et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc

(2011) Jake E. Delmore et al.   CELL

RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia

(2011) Johannes Zuber et al.   NATURE

Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia

(2011) Mark A. Dawson et al.   NATURE

Integrated genomic analyses of ovarian carcinoma

(2011) D. Bell et al.   NATURE

p37δ is a new isoform of PI3K p110δ that increases cell proliferation and is overexpressed in tumors

(2011) S Fransson et al.   ONCOGENE

Deregulation of MYCN, LIN28B and LET7 in a Molecular Subtype of Aggressive High-Grade Serous Ovarian Cancers

(2011) Åslaug Helland et al.   PLoS One

Identification of Tumor Suppressors and Oncogenes from Genomic and Epigenetic Features in Ovarian Cancer

(2011) Kazimierz O. Wrzeszczynski et al.   PLoS One

Targeting MYC dependence in cancer by inhibiting BET bromodomains

(2011) J. A. Mertz et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Inhibition of FGFR2 and FGFR1 increases cisplatin sensitivity in ovarian cancer

(2010) Claire Cole et al.   CANCER BIOLOGY & THERAPY

An Activated ErbB3/NRG1 Autocrine Loop Supports In Vivo Proliferation in Ovarian Cancer Cells

(2010) Qing Sheng et al.   CANCER CELL

Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary

(2010) Ahmed Ashour Ahmed et al.   JOURNAL OF PATHOLOGY

Selective inhibition of BET bromodomains

(2010) Panagis Filippakopoulos et al.   NATURE

Towards a knowledge-based Human Protein Atlas

(2010) Mathias Uhlen et al.   NATURE BIOTECHNOLOGY

Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome

(2008) R. W. Tothill et al.   CLINICAL CANCER RESEARCH

NM23 as a prognostic biomarker in ovarian serous carcinoma

(2008) Bo Sung Youn et al.   MODERN PATHOLOGY